Akums Drugs and Pharmaceuticals Limited

BSE: AKUMS544222ISIN INE09XN01023

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹750.55-9.45 (-1.24%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹839.25
52W low: ₹410.10
Off 52W high: -10.57%
1M return: -6.25%
3M return: +12.69%
6M return: +35.85%
1Y return: +59.39%
20D avg volume: 10,653
50 DMA: ₹764.35
200 DMA: ₹607.32

Key ratios Consolidated

Market cap: ₹11,813 Cr
Current price: ₹750.55
52W high / low: ₹839.25 / ₹410.10
Face value: ₹2.00
P/E: 32.40
P/B: —
EPS (TTM): ₹23.16
Book value / share: —
ROE: —
ROCE: 10.90%
Operating margin: —
Net margin: —
Debt / equity: 0.02
Net debt: ₹-313.05 Cr
Interest cover: 5.06
Dividend yield: 0.40%
Dividend / share (TTM): ₹3.00
Payout: 12.95%
Cash conversion cycle: 79.6 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	1,342	1,167	1,158	1,160	1,018	1,024	1,056	1,010	1,033	1,019	—
	28.91	30.38	35.30	34.33	32.37	26.73	17.55	14.56	13.47	6.55	—
	1,371	1,197	1,193	1,194	1,050	1,051	1,073	1,025	1,047	1,026	—
	1,217	1,058	1,070	1,076	984.22	955.12	1,006	938.70	958.67	938.18	—
	719.46	682.12	586.91	611.25	552.63	547.90	623.85	564.60	505.67	559.50	—
	50.52	26.49	62.93	60.29	56.71	21.08	19.49	30.27	90.86	40.85	—
	224.27	201.43	199.03	189.38	189.27	176.14	183.90	175.60	180.10	176.22	—
	25.68	24.76	23.89	23.74	23.30	23.14	4.54	5.13	11.90	13.02	—
	43.21	41.06	40.12	39.65	37.86	36.92	40.00	44.52	34.87	34.06	—
	156.68	145.09	146.65	144.77	141.22	137.00	138.65	111.06	135.85	122.74	—
	154.74	139.24	123.01	117.79	65.67	95.65	66.92	86.27	87.89	87.48	—
	0.00	0.00	-1.80	-18.23	0.00	0.00	8.22	4.78	3.70	0.00	—
	154.74	139.24	121.22	99.57	65.67	95.65	75.14	91.05	91.59	87.48	—
	40.18	38.26	39.87	31.89	22.98	30.96	-74.47	24.74	24.93	26.27	—
	114.56	100.98	81.34	67.67	42.70	64.69	149.61	66.31	66.65	61.21	—
	7.37	6.53	5.53	4.33	2.66	4.15	9.64	4.26	4.37	4.21	—
Key metrics
	223.63	205.06	185.23	162.96	126.83	155.71	119.68	140.70	138.36	134.56	—
	16.70%	17.60%	16.00%	14.10%	12.50%	15.20%	11.30%	13.90%	13.40%	13.20%	—
	8.50%	8.70%	7.00%	5.80%	4.20%	6.30%	14.20%	6.60%	6.50%	6.00%	—
	4.00%	—	3.30%	—	2.10%	—	2.50%	—	—	—	—
	31.90%	13.90%	9.70%	14.80%	-1.50%	0.50%	—	—	—	—	—
	168.30%	56.10%	-45.60%	2.10%	-35.90%	5.70%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	4,826	4,359	4,118	—
	128.92	128.72	52.12	—
	4,955	4,488	4,170	—
	4,421	4,086	3,842	—
	2,600	2,299	2,254	—
	200.23	201.00	181.47	—
	814.11	753.82	715.82	—
	98.07	94.07	34.60	—
	164.04	154.55	153.45	—
	593.19	569.65	504.42	—
	534.78	402.12	328.56	—
	-20.03	-20.02	16.70	—
	514.77	382.10	345.25	—
	150.20	125.70	1.48	—
	364.55	256.40	343.78	—
	23.76	16.67	22.60	—
Key metrics
	776.88	630.72	533.30	—
	16.10%	14.50%	12.90%	—
	7.55%	5.90%	8.30%	—
	—	10.90%	11.80%	—
	17.50%	5.80%	—	—
	12.76%	-25.40%	—	—
	—	950.67	192.88	—
	—	4.61	1.35	—
	—	0.02	0.00	—
	—	-313.05	-87.54	—
	—	79.6	71.7	—
Balance sheet
	—	5,447	4,113	—
	—	3,560	2,275	—
	—	386.00	101.19	—
	—	796.56	770.30	—
	—	755.71	680.93	—
	—	297.41	198.80	—
	—	1,448	1,390	—
	—	602.16	642.78	—
	—	1,095	893.75	—
	—	72.95	13.65	—
	—	72.95	13.65	—
	—	0.00	0.00	—
	—	3,331	3,064	—
Cash flow
	—	1,181	465.19	—
	—	-930.27	-547.84	—
	—	33.88	72.79	—
	—	230.53	272.31	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	395.05	392.27	338.37	368.61	309.31	332.44	328.75	337.41	328.35	317.27	—
	25.80	26.10	27.73	29.60	27.08	28.55	32.05	33.84	32.12	26.18	—
	420.84	418.38	366.10	398.21	336.39	361.00	360.80	371.25	360.47	343.45	—
	377.00	359.04	341.60	358.54	305.19	301.49	323.75	316.36	298.85	289.18	—
	245.64	253.56	212.81	222.67	202.31	192.55	207.06	206.62	196.47	200.90	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	65.16	58.92	57.88	54.80	54.58	50.74	53.84	50.34	50.38	47.18	—
	3.00	2.48	2.59	2.46	2.08	2.91	2.63	2.29	4.18	6.21	—
	13.51	12.79	12.42	12.15	10.69	10.25	10.09	10.68	9.39	9.38	—
	52.97	48.19	62.04	54.75	46.63	42.77	49.78	—	44.51	41.56	—
	43.85	59.34	24.50	39.67	31.20	59.51	37.05	54.89	61.62	54.27	—
	0.00	0.00	-2.71	-3.81	0.00	0.00	0.00	—	—	—	—
	43.85	59.34	21.79	35.87	31.20	59.51	37.05	54.89	61.62	54.27	—
	11.21	14.50	6.59	7.75	7.74	14.64	9.47	13.72	11.25	12.40	—
	32.64	44.84	15.20	28.11	23.46	44.87	27.59	41.17	50.37	41.88	—
	2.13	2.93	0.99	1.84	1.53	2.93	1.80	2.69	3.38	2.93	—
Key metrics
	60.36	74.61	36.80	50.48	43.97	72.67	49.77	67.86	75.19	69.86	—
	15.30%	19.00%	10.90%	13.70%	14.20%	21.90%	15.10%	20.10%	22.90%	22.00%	—
	8.30%	11.40%	4.50%	7.60%	7.60%	13.50%	8.40%	12.20%	15.30%	13.20%	—
	1.80%	—	1.00%	—	1.40%	—	1.70%	—	—	—	—
	27.70%	18.00%	2.90%	9.20%	-5.80%	4.80%	—	—	—	—	—
	39.10%	-0.10%	-44.90%	-31.70%	-53.40%	7.10%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,494	1,349	1,312	—
	109.23	112.97	124.19	—
	1,604	1,462	1,436	—
	1,436	1,307	1,228	—
	934.68	830.34	811.06	—
	0.00	0.00	0.00	—
	236.76	217.99	201.74	—
	10.53	10.04	15.31	—
	50.87	45.50	39.55	—
	217.95	206.20	170.54	—
	167.36	154.88	207.84	—
	-6.52	-6.52	0.00	—
	160.85	148.37	207.84	—
	40.05	36.73	46.84	—
	120.79	111.64	161.00	—
	7.89	7.29	10.76	—
Key metrics
	222.25	203.91	262.70	—
	14.87%	15.10%	20.00%	—
	8.08%	8.30%	12.30%	—
	—	6.30%	9.40%	—
	14.25%	2.80%	—	—
	-11.89%	-30.70%	—	—
	—	-124.06	-2.60	—
	—	-0.02	0.57	—
	—	0.01	0.00	—
	—	-32.83	-72.56	—
	—	66.6	52.4	—
Balance sheet
	—	2,812	2,685	—
	—	1,324	833.18	—
	—	46.38	76.49	—
	—	217.54	206.14	—
	—	229.93	201.69	—
	—	81.82	48.75	—
	—	403.53	334.92	—
	—	201.40	219.56	—
	—	304.00	309.31	—
	—	13.55	3.93	—
	—	13.55	3.93	—
	—	0.00	0.00	—
	—	2,428	2,305	—
Cash flow
	—	-1.99	91.00	—
	—	-24.97	-458.84	—
	—	-3.15	375.38	—
	—	122.07	93.60	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +14.25%
Profit YoY (TTM): -11.89%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +17.50%
Profit YoY (TTM): +12.76%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 75.27%

Quarter	September 2026	June 2026	December 2025	September 2025
Promoter %	75.27%	75.27%	75.27%	75.27%

Holder	Type	Holding	Previous	Change
AKUMS MASTER TRUST (Sanjeev Jain and Sandeep Jain)	Promoter	40.79%	40.79%	0.00%
Sandeep Jain	Promoter	17.24%	17.24%	0.00%
Sanjeev Jain	Promoter	17.23%	17.23%	0.00%
Franklin India Opportunites Fund	Public	3.90%	4.19%	-0.29%
Akums Employee Benefits Trust	Public	2.73%	2.73%	0.00%
Clarus Capital I	Public	2.23%	2.17%	+0.06%
Bandhan Small Cap Fund	Public	1.13%	1.13%	0.00%
ICICI Prudential Healthcare Fund	Public	1.02%	—	—
Lata Jain	Promoter Group	0.01%	0.01%	0.00%
Delcure Lifesciences Limited	Promoter Group	0.00%	0.00%	0.00%
Manan Jain	Promoter Group	0.00%	0.00%	0.00%
Umang Jain	Promoter Group	0.00%	0.00%	0.00%
American Remedies Lifesciences Limited	Promoter Group	0.00%	0.00%	0.00%
Kanishk Jain	Promoter Group	0.00%	0.00%	0.00%
Archana Jain	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Akums Drugs and Pharmaceuticals Limited	11,813	750.55	32.40	10.90%	+17.50% TTM	+12.76% TTM	+59.39%

Filings & corporate actions

Recent announcements

Audio recording of Earning/ Quarterly Conference Call3 Nov 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication3 Nov 2026 · Company Update / General
Final Report of CRISIL Ratings Limited, Monitoring Agency3 Nov 2026 · Company Update / Monitoring Agency Report
Q2 FY 2026-27 - Investor Presentation2 Nov 2026 · Company Update / Investor Presentation
Press Release2 Nov 2026 · Company Update / Press Release / Media Release
Mr. Sanjay Kumar has been designated as Senior Management Personnel of the Company.2 Nov 2026 · Company Update / Change in Management
Unaudited (standalone & consolidated) financial results for the quarter and half year ended on 30th September, 20262 Nov 2026 · Result / Financial Results
Outcome of the Board Meeting2 Nov 2026 · Board Meeting / Outcome of Board Meeting
Cessation of Mr. Sunil Jaiswal as Senior Management Personnel31 Oct 2026 · Company Update / Change in Management
Intimation of Schedule of the Investors/Analysts Conference Call (group meet) for un-audited financial results of Q2 FY 2026-2728 Oct 2026 · Company Update / Analyst / Investor Meet
Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Board Meeting ....28 Oct 2026 · Board Meeting / Board Meeting
Demand Notice - National Pharmaceuticals Pricing Authority15 Oct 2026 · Company Update / General
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 20189 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Schedule of the Institutional Investors Meets23 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of Schedule of Investors/Analysts Meet16 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of ESG Rating3 Sep 2026 · Company Update / General
Intimation of Schedule of the Investors/Analysts Meet25 Aug 2026 · Company Update / Analyst / Investor Meet
Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25, 202624 Aug 2026 · Company Update / General
Intimation of Schedule of the Investors/Analysts Meet13 Aug 2026 · Company Update / Analyst / Investor Meet
Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 2713 Aug 2026 · Company Update / Earnings Call Transcript
Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 202610 Aug 2026 · Company Update / Analyst / Investor Meet
Link of audio recording of Investors/Analysts Conference Call10 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication10 Aug 2026 · Company Update / General
Monitoring Agency Report for the quarter ended June 30, 202610 Aug 2026 · Company Update / General
Investor Presentation8 Aug 2026 · Company Update / Investor Presentation
Press Release8 Aug 2026 · Company Update / General
Un-audited Financial Results for the Quarter ended 30th June, 20268 Aug 2026 · Result / Financial Results
Un-audited Financial Results for the Quarter ended 30th June, 20268 Aug 2026 · Board Meeting / Outcome of Board Meeting
Intimation of schedule of the Analysts/ Investor Conference Call (Group Meet) for un-audited financial results of Q1 FY275 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of schedule of the Analysts/ Investor Conference Call (Group Meet) for un-audited financial results of Q1 FY275 Aug 2026 · Company Update / Analyst / Investor Meet
Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve the un-audited ....5 Aug 2026 · Board Meeting / Board Meeting
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Oriflame India''s Manufacturing Business23 Jul 2026 · Company Update / Acquisition
Voting Results and Scrutinizer''s Report of the 22nd Annual General Meeting11 Jul 2026 · AGM/EGM / AGM
Proceedings of the 22nd Annual General Meeting of the Company10 Jul 2026 · AGM/EGM / AGM
Certificate pursuant to Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 20188 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Update on penalty imposed by the Deputy Commissioner of State Tax, Gujarat, on Maxcure Nutravedics Limited, wholly owned subsidiary of the Company4 Jul 2026 · Company Update / General
Closure of Trading Window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Advertisements of the 22nd Annual General Meeting of the Company19 Jun 2026 · Company Update / Newspaper Publication
Notice and Integrated Annual Report for the Financial Year 2025-26 to those members who have not registered their e-mail ID''s19 Jun 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 1.0000	3 Jul 2026	3 Jul 2026	—
Special Dividend - Rs. - 2.0000	3 Jul 2026	3 Jul 2026	—

Board meetings

2 Nov 2026 Board Meeting - Financial Results
8 Aug 2026 Board Meeting - Financial Results